From: Jeffrey Epstein <[email protected]>

From: Jeffrey Epstein <[email protected]> To: Boris Nikolic Subject: Re: FW: Materials at request of David Rubenstein Date: Tue, 04 Feb 2014 13:03:47 +0000 just copy caryllyes. ten times better On Tue, Feb 4, 2014 at 2:51 AM, Boris Nikolic > wrote: PPM from the Carlyle Check out 10 years plus 31 Board of Advisors structure etc very similar. 2.5% fee. Co-investments, parallel funds etc. B From: Ryan Schwarz [mailto Sent: Wednesday, April 27, 2011 8:17 AM To: Boris Nikolic Subject: RE: Materials at request of David Rubenstein Boris, Good to see you again in Washington a couple weeks back. I hope you've been well. The placement memo for our new global healthcare fund is now pretty much finalized, and David and I wanted to share it with you. I've attached it to this email. We'd very much like to discuss the fund with you further, and to that end I'd be happy to meet with you in Seattle (or elsewhere) if that would be desirable and would facilitate a discussion. EFTA00871237 Best regards, Ryan Ryan M. Schwarz Managing Director THE CARLYLE GROUP From: Boris Nikolic [mailto: Sent: Friday, March 11, 2011 2:21 AM To: Ryan Schwarz Subject: RE: Materials at request of David Rubenstein Hi Ryan, Great meeting you earlier in day. I made my flight but barely. There was no traffic. It was a luck. Your fund is very interesting and there are a number of synergies. I look forward to discussing it in more details with you as you are developing it. Please keep me posted. If you have any plans of visiting Seattle, please let me know All the best Boris EFTA00871238 From: Ryan Schwarz rmailto: Sent: Wednesday, March 09, 2011 11:28 AM To: Boris Nikolic Subject: Materials at request of David Rubenstein J Boris, David asked me to send you the two attached documents before our meeting tomorrow. One is a high-level concept piece on the global healthcare venture fund idea that we prepared to help David introduce the concept to folks around Carlyle. It provides an overview of the market opportunity as we see it, though of course with much less detail around investment strategy and emphases than will be included in the eventual fund placement memo and presentation. The other is a confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market drug for severe sepsis. I look forward to seeing you in the morning. Ryan Ryan M. Schwarz Managing Director THE CARLYLE GROUP ********************************* *********************************************** < CONFIDENTIALITY NOTICE > The information contained in this transmission is intended only for the person or entity to which it is addressed and may contain confidential, trade secret and/or privileged material. If you are not the intended recipient of this information, do not review, retransmit, disclose, disseminate, use, or take any action in reliance upon, this information. If you received this transmission in error, please contact the sender and destroy all printed copies and delete the material from all computers. ******************************************************************************** < CONFIDENTIALITY NOTICE > The information contained in this transmission is intended only for the person or entity to which it is addressed and may contain confidential, trade secret and/or privileged material. If you are not the intended recipient of EFTA00871239 this information, do not review, retransmit, disclose, disseminate, use, or take any action in reliance upon, this information. If you received this transmission in error, please contact the sender and destroy all printed copies and delete the material from all computers. The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA00871240